Oral Cancer: Integration of Studies for Diagnostic and Therapeutic Precision.
Oral Cancer: Integration of Studies for Diagnostic and Therapeutic Precision.
Adv Dent Res. 2019 Nov;30(2):45-49
Authors: D'Silva NJ, Gutkind JS
Abstract
Head and neck cancers are among the 10 most common cancers in the world and include cancers of the oral cavity, hypopharynx, larynx, nasopharynx, and oropharynx. At least 90% of head and neck cancers are squamous cell carcinomas (SCCs). This summary discusses the integration of clinical and mechanistic studies in achieving diagnostic and therapeutic precision in the context of oral cancer. Specifically, based on recent mechanistic studies, a subsequent study reevaluated current diagnostic criteria of perineural invasion in patients with oral cavity SCC showing that overall survival could be associated with nerve-tumor distance; validation of the findings of this study from a small group of patients could lead to a personalized approach to treatment selection in patients with oral cavity SCC. Moreover, delineation of key pathways in SCC revealed novel treatment targets that can be exploited to develop personalized treatment strategies to achieve long-term remission.
PMID: 31633388 [PubMed - in process]
Source: Adv Dent Res - Category: Dentistry Authors: D'Silva NJ, Gutkind JS Tags: Adv Dent Res Source Type: research
Related Links:
This article is a continuation of the “Do You Know Your Guidelines” series, initiated by the Education committee of the American Head and Neck Society. Treatment guidelines for advanced head and neck squamous cell carcinoma are reviewed here, including the critical roles of radiotherapy, chemotherapy, and the recent application of immunotherapy agents. We will be limiting this discussion to include cancers of the oral cavity, oropharynx, hypopharynx, and larynx. It should be noted that much of the article pertains to human papillomavirus (HPV)‐negative oropharyngeal cancer where applicable, as HPV‐positive ...
Source: Head and Neck - Category: ENT & OMF Authors: Cory D. Fulcher, Missak Haigentz, Thomas J. Ow, Tags: PRACTICE GUIDELINES Source Type: research
CONCLUSION: The current series showed similar patterns of failure as in other tertiary care centres. We did not identify intensity-modulated radiotherapy specific relapse risks.
PMID: 28034680 [PubMed - as supplied by publisher]
Source: Cancer Radiotherapie - Category: Cancer & Oncology Authors: Bednarek C, Nguyen TV, Puyraveau M, Bonnet É, Lescut N, Azélie C, Miny J, Mauvais O, Maurina T, Tochet F, Bosset JF, Thariat J, Sun XS Tags: Cancer Radiother Source Type: research
Conclusion Concurrent chemoradiotherapy using weekly cisplatin at 40mg/m2 per week is an effective, well tolerated regimen allowing most patients to receive at least 5 cycles of chemotherapy. However, a phase III randomized control trial comparing the standard dose of 100mg/m2 cisplatin tri-weekly with a weekly regimen is needed to establish the long term clinical outcome. [...] Thieme Publicações Ltda Rio de Janeiro, BrazilArticle in Thieme eJournals: Table of contents | Abstract | open access Full text
Source: International Archives of Otorhinolaryngology - Category: ENT & OMF Authors: Iqbal, Muhammad Shahid Chaw, Cheng Kovarik, Josef Aslam, Shahzeena Jackson, Aaron Kelly, John Dobrowsky, Werner Kelly, Charles Tags: Original Research Source Type: research
Head and neck cancer (HNC) includes tumours of the oral cavity, oropharynx, hypopharynx, and larynx. Nasopharyngeal cancer is also a HNC sub-site but is usually considered a separate disease with a distinct aetiology and particular characteristics [1]. Approximately 600,000 cases of HNC are diagnosed each year, and HNC accounts for 4% of cancer mortality worldwide [2]. More than 90% of HNC are squamous cell carcinoma [3]. The main risk factors associated with HNC are smoking and alcohol consumption, and the interaction between these factors can increase the risk of HNC [4].
Source: Oral Oncology - Category: Cancer & Oncology Authors: Rejane Augusta de Oliveira Figueiredo, Elisabete Weiderpass, Eloiza Helena Tajara, Peter Str öm, André Lopes Carvalho, Marcos Brasilino de Carvalho, Jossi Ledo Kanda, Raquel Ajub Moyses, Victor Wünsch-Filho Source Type: research
Squamous cell carcinoma (SCC) is the most common malignancy of head and neck region arising from mucosal linings of the upper aerodigestive tract, comprising (1) nasal cavity and paranasal sinuses, (2) nasopharynx, (3) hypopharynx, larynx, and trachea, and (4) oral cavity and oropharynx [1,2]. Head and neck squamous cell carcinomas (HNSCC) are characterized by high morbidity and mortality rates and strong tendency to regional and distant metastasis [1–4]. These tumor characteristics depend on individual properties of neoplastic cells and tumor microenvironment, which is comprised by diverse inflammatory/immune cells ...
Source: Oral Oncology - Category: Cancer & Oncology Authors: Janine Mayra da Silva, Danilo Figueiredo Soave, Tálita Pollyanna Moreira dos Santos, Aline Carvalho Batista, Remo Castro Russo, Mauro Martins Teixeira, Tarcília Aparecida da Silva Tags: Review Source Type: research
Squamous cell carcinoma arises from multiple anatomic subsites in the head and neck region. The risk factors for development of cancers of the oral cavity, oropharynx, hypopharynx, and larynx include tobacco exposure and alcohol dependence, and infection with oncogenic viruses is associated with cancers developing in the nasopharynx, palatine, and lingual tonsils of the oropharynx. The incidence of human papillomavirus–associated oropharyngeal cancer is increasing in developed countries, and by 2020, the annual incidence could surpass that of cervical cancer.
Source: Mayo Clinic Proceedings - Category: Internal Medicine Authors: Shanthi Marur, Arlene A. Forastiere Tags: Symposium on Neoplastic Hematology and Medical Oncology Source Type: research
Head and neck cancer (HNC) ranks fifth among the most common neoplasms, with>500.000 new cases diagnosed every year [1]. HNC comprises a group of malignant tumours located in the upper aero-digestive tract which show similar biological behaviour. The classification of HNC can be based on the anatomic sites of origin (i.e. nasopharynx, nasal cavity, paranasal sinuses, oropharynx, oral cavity, larynx, hypopharynx, salivary glands, thyroid glands) as well as on the histological type, with squamous cell carcinoma being the most frequent type of disease.
Source: Oral Oncology - Category: Cancer & Oncology Authors: Cristiana Bergamini, Laura Locati, Paolo Bossi, Roberta Granata, Salvatore Alfieri, Carlo Resteghini, Martina Imbimbo, Carlo Fallai, Ester Orlandi, Silvia Tana, Nicola Alessandro Iacovelli, Marco Guzzo, Tullio Ibba, Sarah Colombo, Roberto Bianchi, Natalia Source Type: research
Conclusions Preventable risk factor needs to be addressed. Counselling all patients and screening of high risk group along with health awareness creation may be effective in risk reduction.
Source: Clinical Epidemiology and Global Health - Category: Epidemiology Source Type: research
Most commonly head and neck squamous cell carcinoma (HNSCC) are located in the oral cavity, oropharynx, hypopharynx or larynx. Nasopharyngeal carcinoma (NPC) is considered as a separate tumour because of pathology (squamous cell carcinoma or undifferentiated carcinoma), treatment and prognosis. Worldwide the estimated number of HNSCC cases was 599,000 and of NPC 87,000 in 2012, which together comprised 4.8% of all cancer incidences making HNSCC and NPC the seventh most frequent cancer site. Worldwide the estimated number of cancer deaths from HNSCC was 325,000 and from NPC 51,000in 2012, which accounted for 4.6% of all cancer deaths [1].
Source: Critical Reviews in Oncology Hematology - Category: Cancer & Oncology Authors: Dide den Hollander, Ellen Kampman, Carla M.L. van Herpen Source Type: research
Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasa...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
